(COV) Covivio - Ratings and Ratios
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0000064578
Office Buildings, Hotels, Residential Assets
Description: COV Covivio November 05, 2025
Covivio SA (PA:COV) positions itself as a pan-European real-estate operator that blends office, residential, hotel and mixed-use assets to create “vibrant spaces” aligned with user-centric design and sustainability goals.
With a portfolio of roughly €23.6 bn in gross assets, the group reported a FY-2023 occupancy rate of 96 % across its core markets (France, Germany, Italy, and the UK) and a net operating income (NOI) growth of 7 % YoY, driven by strong demand for flexible office solutions and the rebound in tourism-linked hotel occupancy. The company maintains a moderate leverage ratio of ~45 % (net debt/EBITDA), which is below the European REIT average of ~55 % and supports its ability to sustain a dividend yield of about 5.5 %.
Covivio is heavily weighted toward ESG considerations, holding a CDP climate score of A-, a GRESB rating of 88/100 (5-star), and MSCI’s AAA rating. Its shares are constituents of multiple benchmarks-including MSCI, SBF 120, CAC Mid100, EPRA, and several climate-focused indices-underscoring broad market recognition of its responsible-performance framework.
For investors seeking a data-driven assessment of Covivio’s valuation metrics and scenario analysis, a deeper dive on ValueRay can provide the granular financial models needed to gauge upside potential.
COV Stock Overview
| Market Cap in USD | 7,005m |
| Sub-Industry | Diversified REITs |
| IPO / Inception |
COV Stock Ratings
| Growth Rating | 28.6% |
| Fundamental | 63.9% |
| Dividend Rating | 20.3% |
| Return 12m vs S&P 500 | -7.37% |
| Analyst Rating | - |
COV Dividends
| Dividend Yield 12m | 4.52% |
| Yield on Cost 5y | 6.10% |
| Annual Growth 5y | -8.94% |
| Payout Consistency | 91.5% |
| Payout Ratio | 92.8% |
COV Growth Ratios
| Growth Correlation 3m | -34.9% |
| Growth Correlation 12m | 85.6% |
| Growth Correlation 5y | -43.3% |
| CAGR 5y | 5.03% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.12 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.29 |
| Sharpe Ratio 12m | 0.75 |
| Alpha | -15.20 |
| Beta | 1.369 |
| Volatility | 22.23% |
| Current Volume | 71k |
| Average Volume 20d | 80.1k |
| Stop Loss | 53.3 (-3.2%) |
| Signal | 0.39 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-319.5m TTM) > 0 and > 6% of Revenue (6% = 150.2m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -34.34% (prev -18.33%; Δ -16.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.81b > Net Income -319.5m (YES >=105%, WARN >=100%) |
| Net Debt (10.84b) to EBITDA (1.50b) ratio: 7.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (110.8m) change vs 12m ago 16.81% (target <= -2.0% for YES) |
| Gross Margin 64.69% (prev 74.76%; Δ -10.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 9.59% (prev 5.57%; Δ 4.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.71 (EBITDA TTM 1.50b / Interest Expense TTM 166.3m) >= 6 (WARN >= 3) |
Altman Z'' 0.49
| (A) -0.03 = (Total Current Assets 2.68b - Total Current Liabilities 3.54b) / Total Assets 25.63b |
| (B) 0.01 = Retained Earnings (Balance) 341.4m / Total Assets 25.63b |
| (C) 0.05 = EBIT TTM 1.28b / Avg Total Assets 26.10b |
| (D) 0.32 = Book Value of Equity 4.40b / Total Liabilities 13.61b |
| Total Rating: 0.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.87
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 4.77% = 2.39 |
| 3. FCF Margin 30.43% = 7.50 |
| 4. Debt/Equity 1.37 = 1.63 |
| 5. Debt/Ebitda 7.22 = -2.50 |
| 6. ROIC - WACC (= 1.25)% = 1.56 |
| 7. RoE -3.93% = -0.65 |
| 8. Rev. Trend 48.28% = 3.62 |
| 9. EPS Trend 26.54% = 1.33 |
What is the price of COV shares?
As of November 06, 2025, the stock is trading at EUR 55.05 with a total of 70,982 shares traded.
Over the past week, the price has changed by -2.82%, over one month by +0.00%, over three months by -1.96% and over the past year by +11.11%.
Over the past week, the price has changed by -2.82%, over one month by +0.00%, over three months by -1.96% and over the past year by +11.11%.
Is Covivio a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, Covivio is currently (November 2025)
neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 63.87 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COV is around 53.27 EUR . This means that COV is currently overvalued and has a potential downside of -3.23%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COV is around 53.27 EUR . This means that COV is currently overvalued and has a potential downside of -3.23%.
Is COV a buy, sell or hold?
Covivio has no consensus analysts rating.
What are the forecasts/targets for the COV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.6 | 15.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 57.4 | 4.3% |
COV Fundamental Data Overview January 01, 1970
Market Cap USD = 7.00b (6.08b EUR * 1.1525 EUR.USD)
Market Cap EUR = 6.08b (6.08b EUR * 1.0 EUR.EUR)
P/E Trailing = 14.5491
P/E Forward = 11.7371
P/S = 5.3393
P/B = 0.7648
Beta = 1.369
Revenue TTM = 2.50b EUR
EBIT TTM = 1.28b EUR
EBITDA TTM = 1.50b EUR
Long Term Debt = 8.60b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.42b EUR (from shortTermDebt, last quarter)
Debt = 11.24b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.84b EUR (from netDebt column, last quarter)
Enterprise Value = 15.96b EUR (6.08b + Debt 11.24b - CCE 1.36b)
Interest Coverage Ratio = 7.71 (Ebit TTM 1.28b / Interest Expense TTM 166.3m)
FCF Yield = 4.77% (FCF TTM 761.7m / Enterprise Value 15.96b)
FCF Margin = 30.43% (FCF TTM 761.7m / Revenue TTM 2.50b)
Net Margin = -12.76% (Net Income TTM -319.5m / Revenue TTM 2.50b)
Gross Margin = 64.69% ((Revenue TTM 2.50b - Cost of Revenue TTM 883.8m) / Revenue TTM)
Gross Margin QoQ = 62.50% (prev 61.07%)
Tobins Q-Ratio = 0.62 (Enterprise Value 15.96b / Total Assets 25.63b)
Interest Expense / Debt = 1.48% (Interest Expense 166.3m / Debt 11.24b)
Taxrate = 11.78% (67.2m / 570.6m)
NOPAT = 1.13b (EBIT 1.28b * (1 - 11.78%))
Current Ratio = 0.76 (Total Current Assets 2.68b / Total Current Liabilities 3.54b)
Debt / Equity = 1.37 (Debt 11.24b / totalStockholderEquity, last quarter 8.22b)
Debt / EBITDA = 7.22 (Net Debt 10.84b / EBITDA 1.50b)
Debt / FCF = 14.23 (Net Debt 10.84b / FCF TTM 761.7m)
Total Stockholder Equity = 8.14b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.25% (Net Income -319.5m / Total Assets 25.63b)
RoE = -3.93% (Net Income TTM -319.5m / Total Stockholder Equity 8.14b)
RoCE = 7.66% (EBIT 1.28b / Capital Employed (Equity 8.14b + L.T.Debt 8.60b))
RoIC = 5.97% (NOPAT 1.13b / Invested Capital 18.93b)
WACC = 4.73% (E(6.08b)/V(17.32b) * Re(11.06%) + D(11.24b)/V(17.32b) * Rd(1.48%) * (1-Tc(0.12)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 5.18%
[DCF Debug] Terminal Value 64.63% ; FCFE base≈508.4m ; Y1≈431.9m ; Y5≈330.7m
Fair Price DCF = 34.92 (DCF Value 3.87b / Shares Outstanding 110.8m; 5y FCF grow -18.26% → 3.0% )
EPS Correlation: 26.54 | EPS CAGR: 171.7% | SUE: 0.0 | # QB: 0
Revenue Correlation: 48.28 | Revenue CAGR: 71.08% | SUE: 1.08 | # QB: 3
Market Cap EUR = 6.08b (6.08b EUR * 1.0 EUR.EUR)
P/E Trailing = 14.5491
P/E Forward = 11.7371
P/S = 5.3393
P/B = 0.7648
Beta = 1.369
Revenue TTM = 2.50b EUR
EBIT TTM = 1.28b EUR
EBITDA TTM = 1.50b EUR
Long Term Debt = 8.60b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.42b EUR (from shortTermDebt, last quarter)
Debt = 11.24b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.84b EUR (from netDebt column, last quarter)
Enterprise Value = 15.96b EUR (6.08b + Debt 11.24b - CCE 1.36b)
Interest Coverage Ratio = 7.71 (Ebit TTM 1.28b / Interest Expense TTM 166.3m)
FCF Yield = 4.77% (FCF TTM 761.7m / Enterprise Value 15.96b)
FCF Margin = 30.43% (FCF TTM 761.7m / Revenue TTM 2.50b)
Net Margin = -12.76% (Net Income TTM -319.5m / Revenue TTM 2.50b)
Gross Margin = 64.69% ((Revenue TTM 2.50b - Cost of Revenue TTM 883.8m) / Revenue TTM)
Gross Margin QoQ = 62.50% (prev 61.07%)
Tobins Q-Ratio = 0.62 (Enterprise Value 15.96b / Total Assets 25.63b)
Interest Expense / Debt = 1.48% (Interest Expense 166.3m / Debt 11.24b)
Taxrate = 11.78% (67.2m / 570.6m)
NOPAT = 1.13b (EBIT 1.28b * (1 - 11.78%))
Current Ratio = 0.76 (Total Current Assets 2.68b / Total Current Liabilities 3.54b)
Debt / Equity = 1.37 (Debt 11.24b / totalStockholderEquity, last quarter 8.22b)
Debt / EBITDA = 7.22 (Net Debt 10.84b / EBITDA 1.50b)
Debt / FCF = 14.23 (Net Debt 10.84b / FCF TTM 761.7m)
Total Stockholder Equity = 8.14b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.25% (Net Income -319.5m / Total Assets 25.63b)
RoE = -3.93% (Net Income TTM -319.5m / Total Stockholder Equity 8.14b)
RoCE = 7.66% (EBIT 1.28b / Capital Employed (Equity 8.14b + L.T.Debt 8.60b))
RoIC = 5.97% (NOPAT 1.13b / Invested Capital 18.93b)
WACC = 4.73% (E(6.08b)/V(17.32b) * Re(11.06%) + D(11.24b)/V(17.32b) * Rd(1.48%) * (1-Tc(0.12)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 5.18%
[DCF Debug] Terminal Value 64.63% ; FCFE base≈508.4m ; Y1≈431.9m ; Y5≈330.7m
Fair Price DCF = 34.92 (DCF Value 3.87b / Shares Outstanding 110.8m; 5y FCF grow -18.26% → 3.0% )
EPS Correlation: 26.54 | EPS CAGR: 171.7% | SUE: 0.0 | # QB: 0
Revenue Correlation: 48.28 | Revenue CAGR: 71.08% | SUE: 1.08 | # QB: 3